Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Pharmacology

Background:

• Angiopoietin-like 3 protein (ANGPTL3) inhibits lipoprotein lipase and endothelial lipase.
• Loss-of-function mutations in ANGPTL3 are linked to reduced triglycerides, LDL cholesterol, and coronary artery disease risk.

Purpose of the Study:

• To investigate the therapeutic potential of ANGPTL3 inhibition for lipid metabolism disorders.
• To evaluate novel ANGPTL3 inhibitors, including monoclonal antibodies and antisense oligonucleotides.

Main Methods:

• Review of population studies on ANGPTL3 loss-of-function mutations.
• Assessment of evinacumab (monoclonal antibody) in human and mouse models.
• Evaluation of an antisense oligonucleotide targeting ANGPTL3 in healthy human subjects and mouse models.

Main Results:

• ANGPTL3 inhibition demonstrated favorable lipid-lowering effects and an antiatherogenic lipid profile.
• Evinacumab showed positive lipid-lowering action in preclinical models.
• Antisense oligonucleotide treatment reduced circulating ANGPTL3 levels, improved lipid profiles, and decreased atherosclerosis progression in mice.

Conclusions:

• ANGPTL3 inhibition represents a promising therapeutic strategy for dyslipidemia, potentially improving insulin sensitivity independently of the LDL receptor.
• Further clinical trials are necessary to establish the efficacy, safety, and net benefit of ANGPTL3 inhibition in clinical practice.